Introduction
Irinotecan-induced gut toxicity remains a priority concern within the field of supportive care in cancer.
Typically used to treat a variety of solid tumours, irinotecan can cause severe diarrhoea, rectal bleeding and infection in patients, often resulting in dose reductions and treatment delays (1). Irinotecan-induced diarrhoea is clinically very significant as fluid/electrolyte imbalances can lead to renal insufficiency, malnutrition, and extreme dehydration. More importantly, these side effects have severe psychological impacts for patients and significantly effects the ability to deliver optimal treatment (2) . Despite both its prevalence and clinical significance, the precise mechanisms that underpin gut toxicity remain unclear and therapeutic options for patients are limited (1).
The broadly accepted pathophysiology of chemotherapy-induced gut toxicity (CIGT) comprises five continuous and overlapping phases described by Sonis (3) . Although this model can be applied to most chemotherapeutic agents, each treatment modality has unique pathological features due to differences in the metabolism and pharmacokinetics of each anticancer drug. In the case of irinotecan, its unique enterohepatic recirculation is thought to be responsible for the high levels of intestinal toxicity.
Irinotecan serves as the water-soluble precursor of the lipophilic metabolite SN-38, which is formed by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperdino side chain (4) . SN-38 is glucuronidated to the non-toxic SN-38 glucuronide (SN-38G) in the liver via the uridine-diphospho-glucuronosyl transferase (UGT1A) enzyme family, which then releases SN-38G into the intestine for elimination (4) . However, in the intestinal lumen, bacterial -glucuronidases regenerate SN-38 from SN-38G (5) . This unique metabolic pathway not only results in high levels of intestinal toxicity, but also highlights the key relationship between toxicity and the gut microbiome (5).
The gut microbiome has received significant attention for its role in the development of gut toxicity following chemotherapy, with documented changes in the balance of commensal and pathogenic bacteria following numerous chemotherapeutic agents (5) (6) (7) . In light of these findings, the interaction between the gut microbiome and innate mucosal immune system has also gained interest, with particular emphasis on the impact of toll-like receptor (TLR) signaling (8) (9) (10) . TLRs are a family of transmembrane protein receptors recognising a diverse range of signals on exogenous and endogenous substances considered to be 'dangerous', and hence warranting activation of the innate immune system for host survival (11) (12) (13) . TLR4 has been most extensively characterised as it recognises, and responds to, lipopolysaccharide (LPS) from gram-negative bacteria. We have shown that TLR4 is overexpressed in the gut during peak injury (14) and is undetectable at later time points associated with healing (15) .
Further, TLR4 is thought to induce an exacerbated innate immune response resulting in a heightened toxicity profile. This mechanism is particularly relevant in the setting of irinotecan-induced gut toxicity, as our preliminary in silico docking data indicate that SN-38 has the potential to act as a ligand for the TLR4/MD-2 complex.
TLR4 has also been hypothesised to mediate chemotherapy-induced pain through central glial activation (9) , with strong clinical evidence showing chemotherapy-induced gut toxicity is often paralleled by the symptom of pain (16, 17) . This is suggestive of common underlying mechanisms. The ubiquitous involvement of the innate immune system in both chemotherapy-induced pain and gut toxicity therefore makes TLR4 a potentially overlooked candidate in the pathophysiology of these toxicities. We therefore hypothesise that TLR4-mediated signaling plays a central role in the development of irinotecan-induced gut toxicity and pain.
Materials and Methods

Animal Model and Ethics
The study was approved by the Animal Ethics Committee of the University of Adelaide and complied with National Health and Research Council (Australia) Code of Practice for Animal Care in Research and Training (2014). Mice were group housed in ventilated cages with three to five animals per cage.
They were housed in approved conditions on a 12 h light/dark cycle. Food and water were provided ad libitum.
Experimental Design
All mice were on a BALB/c background. Forty-two female BALB/c-wild-type (WT) and BALB/c-
Tlr4
-/-billy mice (ntotal=84) weighing between 18-25 g (10-13 weeks) were used. WT BALB/c mice were obtained from the University of Adelaide Laboratory Animal Service (SA, Australia), and BALB/c-
-/-billy mice, back-crossed onto BALB/c for more than 10 generations, were kindly sourced from Professor Paul Foster from the University of Newcastle (NSW, Australia) and were originally sourced from Osaka, Japan (18) . All BALB/c-Tlr4 -/-billy mice were homozygous null mutants and hence expressed no detectable TLR4 mRNA or protein (personal communication MRH). Mice were treated with a single 270 mg/kg intraperitoneal (i.p.) dose of irinotecan hydrochloride (kindly provided by Pharmacia/Pfizer, Mich, USA) prepared in a sortibol/lactic acid buffer (45mg/ml sorbitol/0.9mg/ml lactic acid; pH 3.4; Sigma-Aldrich, NSW, Australia; D-sorbitol #S1876, lactic acid #252476), which was shown in pilot work to cause reproducible diarrhoea with no mortality. Control mice received the sorbitol/lactic acid buffer only. All mice received 0.03 mg/kg of atropine subcutaneously (s.c.)
immediately prior to treatment to reduce the cholinergic response to irinotecan. Mice were randomly assigned to treatment groups and killed at 6 h, 24 h, 48 h, 72 h and 96 h. Mice were anaesthetised using 200 mg/kg i.p. ilium sodium pentobarbital (60 mg/ml) and blood was collected from the facial vein.
They were then killed via transcardial perfusion with cold, sterile 1 X PBS (pH 7.4) followed by 4% paraformaldehyde (PFA) in 0.1 M PBS (pH 7.4).
Clinical assessment of gut toxicity
All mice were monitored four times daily for the presence of diarrhoea and other clinical parameters.
Diarrhoea was quantified (by two independent assessors) using a validated grading system where 0 = no diarrhoea, 1 = mild perianal staining, 2 = moderate staining covering hind legs, and 3 = severe staining covering hind legs and abdomen with continual anal leakage (19) . Mice were weighed daily to track weight loss/gain. Mice were killed if they displayed ≥15% weight loss or significant distress and clinical deterioration, in compliance with animal ethical requirements.
Facial grimace criteria
Chemotherapy-induced pain was measured by two independent assessors, in a blinded manner, 4 times daily in all mice using the validated rodent facial grimace criteria (20) , as previously published by our group (17) . Briefly, the scoring method consists of five distinct criteria: orbital tightening, cheek bulge, nose bulge, ear position and whisker position. Each criterion was scored as 0 = absent, 1 = moderate and 2 = severe. Please refer to Table S1 for detailed breakdown of scoring criteria.
Tissue preparation
Gastrointestinal Tract Following anesthesia with sodium pentobarbital, mice with perfused with chilled, sterile 1 X PBS (pH 7.4). The entire gastrointestinal tract from pyloric sphincter to rectum was dissected prior to perfusion with 4% PFA and flushed with chilled 1 X PBS (pH 7.4) to remove intestinal contents. Both the small and large intestines were weighed immediately after resection.
Samples (1 cm in length) of jejunum, ileum and colon were collected and (1) drop-fixed using 10% neutral buffered saline for processing and embedding into paraffin wax, or (2) stored in RNAlater® (Sigma Aldrich, NSW, Australia; #R0901) at -20 o C for molecular analyses.
Central Nervous System Mice were perfused with 4% PFA and the vertebral column dissected.
Vertebral bodies were removed to expose the entire spinal cord. The entire spinal cord from cervical to lumbar regions was removed and the lumbar region prepared for further analysis (L3/L4). The mice were then decapitated and the brain extracted. All tissue stored in 4% PFA overnight for processing and embedding in paraffin wax.
Bacterial diversity profiling
It is well established that the gut microbiome is involved in the metabolism of irinotecan (21 Using USEARCH tools, sequences were quality filtered, full length duplicate sequences were removed and sorted by abundance. Singetons or unique reads in the data were discarded. Sequences were clustered followed by chimera filtering using the "rdp_gold" database as a reference. To obtain number of reads in each OTU, reads were mapped back to OTUs with a minimum identity of 97%. Using QUIIME, taxonomy was assigned using Greengenes database (version 13_8, Aug 2013).
PEAR assembly read statistics were as follows: WT BALB/c control 59892 / 67175 (89.16%);
BALB/c-Tlr4 -/-billy control 57982 / 65950 (87.92%).
Histopathological analysis
Haematoxylin and eosin (H&E) staining was performed on 5 m sections of jejunum, ileum and colon cut on a rotary microtome and mounted onto glass Superfrost® microscope slides (Menzel-Gläser, Braunschweig, Germany). Slides were scanned using the NanoZoomer™ (Hamamatsu Photonics, Japan) and assessed with NanoZoomer™ Digital Pathology software view.2 (Histalim, Montpellier, France). The occurrence of eight histological criteria in the jejunum and ileum were examined to generate a total tissue injury score (26) . These criteria were villous fusion, villous atrophy, disruption of brush border and surface enterocytes, crypt loss/architectural disruption, disruption of crypt cells, infiltration of polymorphonuclear cells and lymphocytes, dilation of lymphatics and capillaries, and oedema. In the colon, the latter six criteria were examined. Each parameter was scored as present = 1 or absent = 0 in a blinded fashion by two independent assessors (HRW/KRS).
Immunohistochemistry
Immunohistochemical assessment of cellular markers of apoptosis and proliferation
Immunohistochemistry ( before being subjected to heat-mediated antigen retrieval using 0.1 M citrate buffer (pH 6.0). Nonspecific binding was blocked by 3% normal horse serum (NHS; Sigma-Aldrich, NSW, Australia) for 30 min at room temperature. Primary antibodies were applied, using 3% NHS as the diluent, overnight at room temperature in a humid chamber (GFAP 2 μg/ml; Iba-1 0.1 μg/ml). Following incubation with the primary antibody, a secondary goat biotinylated anti-mouse/rabbit IgG (6 μg/ml) was applied to sections for 30 min at room temperature (Vector Laboratories, California, USA; anti-mouse #BA-9200;
anti-rabbit #BA-1000). After a further PBS wash (2 x 3 min), slides were incubated with pierce streptavidin peroxidase conjugate at 2 μg/ml (ThermoFisher Scientific, Vic, Australia; #21130) for 30 min at room temperature followed by another rinse with 0.1 M PBS. The immunocomplex was then visualised with precipitation of DAB (Sigma-Aldrich, NSW Australia; #D-5637) in the presence of hydrogen peroxide (3%). Slides were washed to remove excess DAB and lightly counterstained with haematoxylin, dehydrated and mounted with DePeX from histolene. Slides were scanned using the NanoZoomer™ (Hamamatsu Photonics, Japan) and assessed with NanoZoomer™ Digital Pathology software (Histalim, Montpellier, France). Staining was assessed in the dorsal column of the lumbar spinal cord using ImageJ 1.49 software and the validated colour deconvolution method (28).
Immunohistochemical assessment of blood brain barrier permeability
Immunohistochemical analysis was also performed on 5 m sections of brain, cut (mid-sagitally) on a rotary microtome and mounted onto Superfrost® microscope slides (Menzel-Gläser, Braunschweig, Germany). Immunostaining was performed using a rabbit polyclonal anti-human albumin antibody (Dako, Denmark; #A0001) as per the method described in 2.3.2. No antigen retrieval was required.
Staining was assessed using a semi-quantitative grading system where 0 = no staining, 1 = mild staining with leakage localised to one region, 2 = moderate staining with two unrelated sites of leakage and 3 = intestine staining with 3 unrelated sites or global leakage. Staining was assessed in a blinded fashion by two independent assessors (HRW, JM).
Assessment of in vivo intestinal permeability
FITC-dextran assay
Three hours prior to kill time points, mice received a 500 mg/kg dose (75 mg/ml) of 4 kDa fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, NSW, Australia; #46944) via oral gavage. Blood was collected from the facial vein into Multivette 600 Serum-Gel with Clotting Activator capillary tubes (Sarstedt, Numbretcht, Germany; #15.1670.100) and stored on ice for 30 min. Samples were centrifuged at 11,000 x g for 5 min at room temperature and the serum isolated. Serum samples were diluted 1:3 with 1 X PBS and quantified using the BioTek Synergy™ Mx Microplate Reader (BioTek, Vermont, USA) and Gen5 version 2.00.18 software relative to a standard curve (range 0.0001-10 g/ml).
Serum Limulus Amebocyte Lysate (LAL) endotoxin assay
The Limulus Amebocyte Lysate (LAL) endotoxin assay was run on serum samples isolated from blood collected from the facial vein into Multivette 600 Serum-Gel with Clotting Activator capillary tubes (Sarstedt, Numbretcht, Germany; #15.1670.100). The LAL QCL-1000 TM endotoxin detection kit (Lonza, Basel, Switzerland; #50-647U, 50-648U) was then used to quantify serum endotoxin, as per manufacturer's guidelines. Endotoxin concentration was determined relative to a linear standard curve (range 0.1-1 EU/ml).
Tissue cytokine protein quantification
Protein extraction
Irinotecan causes global gastrointestinal damage, however damage is typically most severe in the ileum and colon. Proinflammatory cytokine expression was therefore assessed using 30 mg of ileal and and two quality controls provided by Merck Millipore.
Statistical analysis
Data were compared using Prism version 7.0 (GraphPad® Software, San Diego, USA). A D'AgostinoPearson omnibus test was used to assess normality. When normality was confirmed, a two-way analysis of variance (ANOVA) with appropriate post hoc testing were performed to identify statistical significance between groups. In other cases, a Kruskal-Wallis test with Dunn's multiple comparisons test and Bonferroni correction was performed. Diarrhoea data was assessed using a Chi-square test (29) . A p-value of ˂0.05 was considered significant.
Results
Bacterial diversity profiling
Bacterial profiling showed comparable microbiome composition in both WT and BALB/c-Tlr4 
Irinotecan-induced pain is associated with TLR4-dependent astrocytic GFAP expression
Facial grimace criteria peaked at 6 h in both treated animals groups, reducing steadily for the remainder of the experimental time-course ( Figure 5A ). From 6 to 72 h, BALB/c-Tlr4 -/-billy mice had reduced facial grimace criteria compared to WT mice (***p<0.0001). Elevated GFAP staining, indicative of astrocyte activation, was seen at 6 h in WT animals compared to controls (#p=0.004) ( Figure 5B ).
GFAP staining was significantly greater in WT compared to BALB/c-Tlr4
-/-billy mice at 6 (*p=0.008) and 72 h (*p=0.01). No change was seen in Iba-1 staining in any animals ( Figure 5C ; p>0.05).
Representative images ( Figure 5D ) support activation of astrocytes with obvious changes in phenotype 6 h after irinotecan in WT mice.
Irinotecan increases blood brain barrier permeability to albumin
Elevated albumin staining was seen in WT (#p=0.0001) and BALB/c-Tlr4 -/-billy mice (^p=0.03) at 24 h, and in WT mice at 48 and 72 h (#p=0.006 and #p=0.03, respectively) ( Figure 6A ), although there was no difference between WT and BALB/c-Tlr4 -/-billy mice (p>0.05). Both parenchymal ( Figure 6C ) and perivascular ( Figure 6D ) albumin was evident in WT and BALB/c-Tlr4 -/-billy mice treated with irinotecan, with minimal leakage in control animals ( Figure 6B ).
Discussion
TLR4 has been hypothesised to play a key role in the development of both chemotherapy-induced gut toxicity and pain (9, 17) . Results from the current study support this newly proposed hypothesis, highlighting significant improvements in symptomatic parameters of gut toxicity and histopathological markers in BALB/c-Tlr4 -/-billy mice treated with irinotecan. This study is also the first to show paralleled improvements in in vivo pain markers and central glial reactivity following irinotecan.
The gut microbiota is critical in regulating the severity of gut toxicity, with increased levels of LPSproducing, gram-negative bacteria correlating with diarrhoea severity (5, 30) . Comparable levels of major phylogenies (fermicutes, bacteroidetes) were seen in WT and BALB/c-Tlr4 -/-billy mice at baseline.
However, small variations were seen in two relatively low abundance microbes. These differences seen in the composition of the gut microbiome in WT and BALB/c-Tlr4 -/-billy mice are not surprising given the wealth of emerging evidence indicating that both genetic and environment factors, such as breeding rooms//facilities, weigh significantly on the composition of the gut microbiome (31).
At baseline, TLR4 knockout mice exhibited higher levels of the TM7 bacterial phyla. Little is known about this bacterial phylogeny, however it has been suggested to contribute to inflammatory pathologies within the gastrointestinal tract (32) . More importantly, BALB/c-Tlr4 -/-billy mice had elevated levels of -glucuronidase-producing proteobacteria, likely increasing the rate of SN-38 reactivation, and thus worsened gut toxicity. Despite this predisposition, BALB/c-Tlr4 -/-billy mice showed improvements in both the duration and severity of symptoms compared to WT mice. This finding compliments recent research showing that germ-free mice experienced less severe irinotecaninduced gut toxicity compared to conventional mice (33) . Most importantly, the germ-free mice also had higher levels of unbound SN-38 and higher -glucuronidases activity. Comparatively, depletion of the gut microbiome with oral antibiotics has shown to be effective in reducing irinotecan-induced diarrhoea (34) . It is now essential to determine if these improvements are the results of reduced microbial metabolism and SN-38 reactivation, or the result of reduced TLR4-mediated signaling.
Determination of which factor contributes more significantly to clinical outcomes would therefore better direct therapeutic research efforts.
Extensive literature exists showing the protective effect of TLR4 deletion in an inflammatory setting, however this appears to be limited to only acute insults, with TLR4 deficiency exacerbating chronic inflammatory diseases (35 (36) . Importantly, this study showed that TLR4 and TLR2 appear to have opposing roles, with both genetic deletion and pharmacological inhibition of TLR2
worsening methotrexate-induced damage (36) . It appears that TLR2 has paradoxical roles in chemotherapy-induced gut toxicity, with improvements seen in Tlr2 -/-mice treated with irinotecan.
This study also showed that Myd88 -/-mice were also protected from developing severe irinotecaninduced gut toxicity, reiterating the importance of TLR4-dependent signaling (36) . Despite support for TLR4 deletion providing protection against chemotherapy-induced gut toxicity, this does not appear to be the case for acute and chronic colitis, with Tlr4 -/-mice more susceptible to ulceration and bleeding (35) . Although the unique mechanisms to each effect are not understood, these data do imply ambivalent roles for TLR4 in different inflammatory-based pathologies in the gastrointestinal tract.
It is well established that irinotecan-induced gut toxicity occurs through apoptosis of crypt epithelial cells through the gastrointestinal tract and consequently apoptosis is an established marker of toxicity severity (27) . Our results showed significantly decreased levels of apoptosis in the jejunum and ileum of irinotecan-treated BALB/c-Tlr4 -/-billy mice. This supports recent research suggesting that TLR4 signaling contributes to intestinal stem cell apoptosis through endoplasmic reticular stress-related mechanisms (37) . We also saw levels of proliferation inversely parallel these changes in cellular dynamics. This is of great clinical significance as apoptosis is one of the initial steps in the cascade of biological events that results in the development of gut toxicity. If TLR4 deletion is able to profoundly impact such an early mediator of toxicity, it provides an excellent opportunity to intervene prior to architectural tissue damage, inflammation and bacterial translocation.
In this study, increased FITC-dextran and endotoxin permeability were seen in irinotecan-treated WT mice, indicative of altered intestinal barrier function. Importantly, Tlr4 -/-maintained intestinal barrier function with no significant changes in FITC-dextran permeability and decreased LPS translocation.
Surprisingly, BALB/c-Tlr4 -/-billy mice only showed mild improvements in serum endotoxin compared to WT mice and this did not appear to reflect the differences in intestinal damage. The failure to show differences at most time points in this study could be explained by evidence suggesting that TLR4 on hepatocytes is required for complete endotoxin clearance (38) .
Reducing bacterial translocation has profound implications for systemic inflammatory responses and the exacerbation of direct mucosal cytotoxicity. Highlighting this pathobiological mechanism, BALB/c-Tlr4 -/-billy mice, displayed less severe intestinal inflammation compared to WT mice. The most significant difference was seen for IL-6, in which BALB/c-Tlr4 -/-billy mice showed no increase after treatment, supporting the idea that TLR4-dependent NFB activation is required for the release of IL-6 from macrophages (39) . Stunted IL-6 production has also been seen in MyD88 deficient mice (40) and
The current study also identified, for the first time, disruption of the blood brain barrier in animals treated with irinotecan. Blood brain barrier disruption has been hypothesised to contribute to the development of 'chemobrain' and cognitive impairment seen following chemotherapy, allowing cytotoxic agents direct access to the CNS (42) . It has also been suggested uncontrolled blood brain barrier transit may potentiate the ability of peripheral inflammation to influence central pain signaling.
It is becoming increasingly recognised that TLR4, expressed on centrally located glia, is able to recognise and respond to peripherally derived LPS and inflammatory mediators (9) . We have shown translocation of LPS to systemic circulation following chemotherapy treatment, reflecting the swing towards a gram-negative, pathogenic gut microbiome profile following chemotherapy. Despite this, we saw no association serum LPS, glial activation and pain. Instead, astrocytic activation appeared to occur bimodally, with increases in GFAP staining seen at 6 and 72 h. This suggests that cellular events associated with apoptosis (which peaks at 6 h), or inflammation may be more important in TLR4- (45) (46) (47) . In addition, although not assessed in the current study, future work will need to clarify the role of TLR4 in normal gastrointestinal motility patterns given recent research implicating TLR4 in altered motility patterns following opioid treatment (48, 49).
Conclusions
Given the ubiquitous involvement of the innate immune system, particularly TLR4, in gut homeostasis and central pain signaling, it presents as a potentially overlooked candidate in the treatment of chemotherapy-induced gut toxicity and pain. Our research has demonstrated that TLR4 is pivotal in the development of both toxicities. This research not only improves our understanding of the underlying mechanisms involved, but also reveals a promising opportunity to intervene in the complex pathophysiology of these dose-limiting side effects of chemotherapy. Research efforts must now be targeted at tailoring methods of inhibiting TLR4, keeping in mind the potential effects on tumour burden and gastrointestinal function. 
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